Shirit Einav, Medicine (Infectious Diseases)
Novel Approaches to Antiviral Therapy
Shirit Einav - Professor of Medicine (Infectious Diseases) and of Microbiology & Immunology
Seed Grant Committee Member, Scientific Leadership Council Member, Bio-X Affiliated Faculty
The Einav lab's goal is to better understand the roles of virus-host interactions in the viral lifecycle and pathogenesis and identify host functions required by multiple unrelated viruses.
Stanford Bio-X Seed Grants
Interdisciplinary Initiatives Program Seed Grant: Better understanding microbial-associated congenital neurodevelopmental disorders via a systems biology approach in discordant dizygotic twins
Interdisciplinary Initiatives Program Round 12 - 2024
Better Understanding and Predicting Viral Sepsis
Interdisciplinary Initiatives Program Round 8 - 2016
Research News
Going atom-by-atom, Stanford researchers craft a new precision drug for fighting COVID-19
March 13, 2024 - Stanford News
The rapidly evolving SARS-CoV-2 virus threatens the progress made in curbing the COVID-19 pandemic. Stanford Bio-X...
Drug combination defeats dengue, Ebola in mice
February 27, 2017 - Stanford Medicine News Center
To develop a potential antiviral treatment, Bio-X affiliates Shirit Einav and Claude Nagamine,...
Stanford scientists working to develop broad-spectrum antiviral drug
September 26, 2013 - Stanford Report
Research funded by a Bio-X IIP Seed Grant awarded to Drs. Stephen Quake and Shirit Einav in 2012.